As the GLP-1 conversation continues to evolve, Omada Health is updating its industry FAQs to deliver timely data and insights for buyers. In the first half of the year, we focused on weight loss quality vs. quantity, addressing usage and costs, off-ramping protocols, and equity issues. This quarter, we’re drilling into emerging details of the GLP-1 experience, including compounded GLP-1s, how to manage the drug’s impact on body composition, and ways to assess the value of virtual companion programs.